- Record 2014 fourth quarter earnings per share of $1.19 compared with $1.13 in the 2013 fourth quarter - 2014 full year earnings per share were $4.93 compared with $4.44 for 2013, which included a $0.20 per share benefit due to the reduction of the United earnout liability
- 2015 full year earnings per share guidance range of $4.50 to $4.70, including an estimated $0.15 per share year over year increase in pension expense, compared with $4.93 for 2014 - 2015 first quarter earnings per share guidance of $1.05 to $1.15 compared with $1.09 in the 2014 first quarter - Purchased $100 million, or 1,263,947 shares, of Kirby common stock since December 23, 2014 at an average price of $79.12 per share - Kirby's Board of Directors authorized the repurchase of an additional 2,000,000 shares, bringing the total unused repurchase authorization to 3,685,000 shares HOUSTON , Jan.
- 2014 fourth quarter earnings per share guidance range lowered to $1.10 to $1.20 from $1.30 to $1.40 per share - 2014 full year earnings per share guidance lowered to $4.84 to $4.94 from $5.04 to $5.14 per share
- A conference call to discuss revised guidance is scheduled for tomorrow, December 18, at 7:30 am Central Standard Time - Kirby to announce 2014 fourth quarter and full year results on Wednesday, January 28, 2015, with a conference call on Thursday, January 29, 2015 HOUSTON , Dec.
Sign-up for Kitara Media Corp. Adjourns Special Meeting of Stockholders Relating to Proposed Business Combination to January 26, 2015 and Anticipates Consummating Merger with Future Ads Shortly Thereafter investment picks
Sign-up for Kite Pharma Announces Expanded Agreement with Tel Aviv Sourasky Medical Center and Pioneering Researcher Professor Zelig Eshhar to Develop Novel Chimeric Antigen Receptor (CAR) Approaches for Cancer Immunotherapy investment picks
Sign-up for Kite Pharma Submits Investigational New Drug Application for Phase 1/2 Trial of KTE-C19, Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, for the Treatment of Refractory Aggressive Non-Hodgkin Lymphoma investment picks
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.